J&J Submits Supplemental BLA for Darzalex Faspro to FDA
Johnson & Johnson Submits Application to FDA for Multiple Myeloma Treatment
J&J Backtracks on Plan Aimed at Hospital Drug-Discount Program -- WSJ
Express News | Johnson & Johnson Files for U.S. FDA Approval of Darzalex Faspro®-Based Quadruplet Regimen for Newly Diagnosed Multiple Myeloma Patients for Whom Transplant Is Not Planned
80 Hedge Funds Hold Stakes in Johnson & Johnson (JNJ) as of Q2 2024
Johnson & Johnson Price Target Maintained With a $215.00/Share by Cantor Fitzgerald